Scientific Clinical | NANOBIOTIX: Positive phase II/III results for NBTXR3 in Soft Tissue Sarcoma presented at ESMO
(WorldNews France)

NANOBIOTIX: POSITIVE PHASE II/III RESULTS FOR NBTXR3 IN SOFT TISSUE SARCOMA PRESENTED AT ESMO o Dr. Sylvie Bonvalot, Head of Sarcoma and Complex Tumor Surgery Unit at Institut Curie - Paris, presented first-in-class NBTXR3 positive Phase II/III results during the Sarcoma Proffered Paper Oral session at ESMO o NBTXR3 is the first radiotherapy enhancer to demonstrate clinically meaningful benefit for patients with locally advanced Soft Tissue Sarcoma compared to radiotherapy alone o The Primary and main Secondary Endpoints were met: pathological Complete Response Rate, R0 Resection Margin and percentage of Necrosis/Infarction o In the subgroup of patients having an advanced disease, 4-times...